1.915
前日終値:
$1.95
開ける:
$1.95
24時間の取引高:
1.35M
Relative Volume:
0.31
時価総額:
$860.87M
収益:
-
当期純損益:
$-75.80M
株価収益率:
-5.4714
EPS:
-0.35
ネットキャッシュフロー:
$-68.07M
1週間 パフォーマンス:
-6.59%
1か月 パフォーマンス:
-9.67%
6か月 パフォーマンス:
-28.01%
1年 パフォーマンス:
-39.40%
Nuvation Bio Inc Stock (NUVB) Company Profile
名前
Nuvation Bio Inc
セクター
電話
(415) 754-3517
住所
357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO
NUVB を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
NUVB
Nuvation Bio Inc
|
1.9135 | 860.87M | 0 | -75.80M | -68.07M | -0.35 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
449.77 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
530.20 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
322.76 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
562.99 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
242.03 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-04-23 | 開始されました | Citizens JMP | Mkt Outperform |
2024-03-27 | アップグレード | Jefferies | Hold → Buy |
2024-03-26 | アップグレード | BTIG Research | Neutral → Buy |
2023-01-06 | ダウングレード | Jefferies | Buy → Hold |
2022-08-02 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
2022-08-02 | ダウングレード | BTIG Research | Buy → Neutral |
2022-05-04 | 開始されました | H.C. Wainwright | Buy |
2021-10-15 | 再開されました | BTIG Research | Buy |
2021-04-06 | 開始されました | RBC Capital Mkts | Outperform |
2021-03-08 | 開始されました | BMO Capital Markets | Outperform |
2021-03-08 | 開始されました | BTIG Research | Buy |
2021-03-08 | 開始されました | Cowen | Outperform |
2021-03-08 | 開始されました | Jefferies | Buy |
2021-03-08 | 開始されました | Wedbush | Outperform |
すべてを表示
Nuvation Bio Inc (NUVB) 最新ニュース
Insider Buying: Stacy Markel Acquires 10,000 Shares of Nuvation Bio Inc (NUVB) - GuruFocus
Nuvation Bio: A Justified Fall Based On Post-Marketing Requirements (NYSE:NUVB) - Seeking Alpha
Nuvation Bio (NUVB): RBC Capital Maintains Rating, Lowers Price - GuruFocus
Nuvation Bio (NUVB): RBC Capital Maintains Rating, Lowers Price Target | NUVB Stock News - GuruFocus
Nuvation Bio (NUVB) Target Price Revised Amid Commercial Shift | NUVB Stock News - GuruFocus
RBC Cuts Price Target on Nuvation Bio to $6 From $10, Keeps Outperform, Speculative Risk - MarketScreener
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for IBTROZI™ (taletrectinib), Manufactured by Nuvation Bio Inc. - The Manila Times
Onco360 Has Been Selected as a National Specialty Pharmacy - GlobeNewswire
Nuvation Bio’s SWOT analysis: FDA approval boosts stock prospects By Investing.com - Investing.com Nigeria
Nuvation Bio’s SWOT analysis: FDA approval boosts stock prospects - Investing.com
Nuvation Bio stock holds steady as FDA approves lung cancer drug - Investing.com India
Buy Rating for Nuvation Bio’s IBTROZI: FDA Approval and Competitive Edge in ROS1+ NSCLC Treatment - TipRanks
Nuvation Bio price target maintained at $6 by Citizens JMP - Investing.com South Africa
FDA Approves Nuvation Bio’s Ibtrozi for Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer - PharmExec
'Life is too short to work on things that are mediocre': Why this biotech CEO's 2nd drug approval is a big deal - The Business Journals
U.S. FDA Approves Nuvation Bio’s Ibtrozi - Contract Pharma
Nuvation Scores First FDA Nod With Oral Lung Cancer Drug - BioSpace
Nuvation Bio (NUVB) Shares Decline Despite FDA Approval of Ibtro - GuruFocus
FDA approves Nuvation Bio’s TKI inhibitor Ibtrozi to treat rare form of lung cancer - PMLiVE
Nuvation Bio stock falls after FDA approves lung cancer drug By Investing.com - Investing.com Canada
FDA approves Nuvation Bio’s Ibtrozi for ROS1-positive NSCLC - The Pharma Letter
Nuvation Bio stock falls after FDA approves lung cancer drug - Investing.com
Nuvation Bio granted FDA approval for lung cancer therapy Ibtrozi - MSN
Nuvation Bio (NUVB) Gains FDA Approval for Lung Cancer Drug Ibtr - GuruFocus
Nuvation Bio (NUVB) Trading Halted Amidst Anticipated Announceme - GuruFocus
FDA clears Nuvation lung cancer drug, setting up battle with Bristol Myers and Roche - BioPharma Dive
Nuvation Bio’s IBTROZI Receives FDA Approval - TipRanks
Nuvation Set For First Launch With Ibtrozi In Lung Cancer - insights.citeline.com
Nuvation Bio (NUVB) Gains FDA Approval for Advanced Lung Cancer Drug IBTROZI | NUVB Stock News - GuruFocus
Nuvation Bio (NUVB) Stock Rating Maintained at Outperform by Wed - GuruFocus
Nuvation Bio (NUVB) Stock Rating Maintained at Outperform by Wedbush | NUVB Stock News - GuruFocus
# FDA approves Nuvation Bio’s lung cancer drug taletrectinib By Investing.com - Investing.com South Africa
US FDA approves Nuvation Bio’s lung cancer therapy - WSAU
US FDA approves Nuvation Bio's rare lung cancer drug - Reuters
U.S. Food and Drug Administration Approves Nuvation Bio's IBTROZ - GuruFocus
Nuvation Bio's Ibtrozi For ROS1-Positive Lung Cancer Wins FDA Approval - Benzinga
Nuvation Bio (NUVB) Gets Boost as FDA Approves Ibtrozi for Lung - GuruFocus
Nuvation Bio (NUVB) Shares Decline Despite FDA Approval of Ibtrozi | NUVB Stock News - GuruFocus
# FDA approves Nuvation Bio’s lung cancer drug taletrectinib - Investing.com
Nuvation Bio (NUVB) Trading Resumes | NUVB Stock News - GuruFocus
Nuvation Bio (NUVB) Gets Boost as FDA Approves Ibtrozi for Lung Cancer | NUVB Stock News - GuruFocus
Nuvation Bio scores first FDA approval for new lung cancer drug - Endpoints News
Nuvation Bio (NUVB) Gains FDA Approval for Advanced Lung Cancer - GuruFocus
Nuvation kinase inhibitor wins FDA approval in non-small cell lung cancer - TipRanks
Nuvation Bio stock in focus as FDA clears Ibtrozi (NUVB:NYSE) - Seeking Alpha
Nuvation Bio announces FDA approval of Ibtrozi for advanced ROS-1+ NSCLC - TipRanks
FDA Grants Approval to Nuvation Bio's Ibtrozi for Lung Cancer Treatment (NUVB) | NUVB Stock News - GuruFocus
U.S. Food and Drug Administration Approves Nuvation Bio’s IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer – Company AnnouncementFT.com - Financial Times
U.S. Food and Drug Administration Approves Nuvation Bio’s IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer - Mid Florida Newspapers
Nuvation Bio (NUVB) Shares Surge Following FDA Approval | NUVB Stock News - GuruFocus
US FDA approves Nuvation Bio's lung cancer therapy - TradingView
Nuvation Bio Inc (NUVB) 財務データ
収益
当期純利益
現金流量
EPS
Nuvation Bio Inc (NUVB) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
Sauvage Philippe | Chief Financial Officer |
Jun 17 '25 |
Buy |
1.79 |
4,000 |
7,160 |
9,902 |
Sauvage Philippe | Chief Financial Officer |
Jun 16 '25 |
Buy |
1.83 |
3,300 |
6,056 |
5,902 |
Sjogren Colleen | Chief Commercial Officer |
Jun 16 '25 |
Buy |
1.81 |
50,000 |
90,350 |
81,000 |
Wentworth Kerry | CHIEF REGULATORY OFFICER |
Jun 16 '25 |
Buy |
1.79 |
50,000 |
89,740 |
50,000 |
Hung David | PRESIDENT AND CEO |
Jun 16 '25 |
Buy |
1.79 |
500,000 |
893,500 |
59,281,054 |
Liu Dongfang | CHIEF MEDICAL OFFICER |
May 02 '25 |
Option Exercise |
1.94 |
20,000 |
38,800 |
32,000 |
Liu Dongfang | CHIEF MEDICAL OFFICER |
May 02 '25 |
Sale |
2.50 |
20,000 |
50,024 |
12,000 |
大文字化:
|
ボリューム (24 時間):